Test of the Month

You have full text access to this OnlineOpen article

Clinical and laboratory diagnosis of von Willebrand disease: A synopsis of the 2008 NHLBI/NIH guidelines†

  1. William L. Nichols1,2,*,
  2. Margaret E. Rick3,
  3. Thomas L. Ortel4,5,
  4. Robert R. Montgomery6,7,
  5. J. Evan Sadler8,
  6. Barbara P. Yawn9,10,
  7. Andra H. James11,
  8. Mae B. Hultin12,
  9. Marilyn J. Manco-Johnson13,14,
  10. Mark Weinstein15

Article first published online: 16 MAR 2009

DOI: 10.1002/ajh.21405

Issue

American Journal of Hematology

American Journal of Hematology

Volume 84, Issue 6, pages 366–370, June 2009

Additional Information

How to Cite

Nichols, W. L., Rick, M. E., Ortel, T. L., Montgomery, R. R., Sadler, J. E., Yawn, B. P., James, A. H., Hultin, M. B., Manco-Johnson, M. J. and Weinstein, M. (2009), Clinical and laboratory diagnosis of von Willebrand disease: A synopsis of the 2008 NHLBI/NIH guidelines. Am. J. Hematol., 84: 366–370. doi: 10.1002/ajh.21405

Author Information

  1. 1

    Special Coagulation Laboratory, Division of Hematopathology, Department of Laboratory Medicine and Pathology, College of Medicine, Mayo Clinic, Rochester, Minnesota

  2. 2

    Coagulation Clinic and Comprehensive Hemophilia Center, Division of Hematology and Internal Medicine, College of Medicine, Mayo Clinic, Rochester, Minnesota

  3. 3

    Hematology Service, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland

  4. 4

    Division of Hematology, Department of Medicine, Duke University Medical Center, Durham, North Carolina

  5. 5

    Clinical Coagulation Laboratory, Department of Pathology, Duke University Medical Center, Durham, North Carolina

  6. 6

    Blood Research Institute, Blood Center of Wisconsin, Medical College of Wisconsin, Milwaukee, Wisconsin

  7. 7

    Section of Pediatric Hematology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin

  8. 8

    Department of Medicine, Washington University, St. Louis, Missouri

  9. 9

    Department of Research, Olmsted Medical Center, Rochester, Minnesota

  10. 10

    Department of Family and Community Medicine, University of Minnesota, Minneapolis, Minnesota

  11. 11

    Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina

  12. 12

    Department of Medicine, Stony Brook University, Stony Brook, New York

  13. 13

    Department of Pediatrics, University of Colorado Denver, Aurora, Colorado

  14. 14

    Center for Cancer and Blood Disorders, Children's Hospital of Denver, Denver, Colorado

  15. 15

    Office of Blood Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Rockville, Maryland

*Special Coagulation Laboratory and Comprehensive Hemophilia Center, Hilton 200, Mayo Clinic, 200 First St SW, Rochester, MN 55905

  1. †

    Authors disclosing potential conflicts of interest are Dr. Andra James (speaking and consulting fees, and research support from CSL Behring, and honoraria from Grifols), Dr. Marilyn Manco-Johnson (speaking and consulting fees, and research support from CSL Behring), Dr. Robert Montgomery (consultant for Baxter, CSL Behring, GTI-Diagnostics, and Astra Zeneca; CSL Behring fellowship for research support), Dr. William Nichols (CSL Behring Humate-P surgical trial study, supervision of “central laboratory” activities at the Mayo Special Coagulation Laboratory, via contract through Mayo Clinical Trials Services), Dr. Thomas Ortel (speaking fee from CSL Behring), and Dr. J. Evan Sadler (consultant and Clinical Advisory Board member for Baxter). Drs. Margaret Rick and Mark Weinstein reported no potential conflicts of interest and contributed to this manuscript in their private capacities, and no official endorsement or support by the National Institutes of Health or the Food and Drug Administration is intended or should be inferred. All other authors reported no potential conflicts of interest.

Publication History

  1. Issue published online: 26 MAY 2009
  2. Article first published online: 16 MAR 2009
  3. Accepted manuscript online: 16 MAR 2009 12:00AM EST
  4. Manuscript Accepted: 9 MAR 2009
  5. Manuscript Revised: 4 MAR 2009
  6. Manuscript Received: 6 JAN 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (310K)

References

  • 1
    The National Heart, Lung, and Blood Institute. The Diagnosis, Evaluation, and Management of Von Willebrand Disease. Bethesda, MD: National Institutes of Health Publication 08-5832. 2007. Available at: http://www.nhlbi.nih.gov/guidelines/vwd.
  • 2
    The National Heart, Lung, and Blood Institute. A Pocket Guide to The Diagnosis, Evaluation, and Management of Von Willebrand Disease. Bethesda, MD: National Institutes of Health Publication 08-5833. 2008. Available at: http://www.nhlbi.nih.gov/guidelines/vwd/vwd_pocket-gde.htm.
  • 3
    Nichols WL,Hultin MB,James AH, et al. von Willebrand disease (VWD): Evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14: 171–232.
    Direct Link:
  • 4
    Chee YL,Crawford YL,Watson HG, et al.; British Committee for Standards in Haematology. Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures. Br J Haematol 2008; 140: 496–504.
    Direct Link:
  • 5
    American Society of Hematology, Practice Committee. 2008 Clinical Practice Guideline on the Evaluation and Management of von Willebrand Disease. Washington, DC. 2008. Available at: http://www.hematology.org/policy/resources/guidelines/VWD_Quick_Reference(rf).pdf.
  • 6
    Sadler JE,Budde U,Eikenboom JCJ, et al. Update on the pathophysiology and classification of von Willebrand disease: A report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4: 2103–2114.
    Direct Link:
  • 7
    Veyradier A,Balian A,Wolf M, et al. Abnormal von Willebrand factor in bleeding angiodysplasias of the digestive tract. Gastroenterology 2001; 120: 346–353.
  • 8
    Shimizu M,Masai H,Miwa Y. Occult gastrointestinal bleeding due to acquired von Willebrand syndrome in a patient with hypertrophic obstructive cardiomyopathy. Intern Med. 2007; 46: 481–485.
  • 9
    Le Tourneau T,Susen S,Caron C, et al. Functional impairment of von Willebrand factor in hypertrophic cardiomyopathy. Circulation 2008; 118: 1550–1557.
  • 10
    Tiede A,Priesack J,Werwitzke S, et al. Diagnostic workup of patients with acquired von Willebrand syndrome: A retrospective single-centre cohort study. J Thromb Haemost 2008; 6: 569–576.
    Direct Link:
  • 11
    Geisen U,Heilmann C,Beyersdorf F, et al. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease. Eur J Cardiothorac Surg 2008; 33: 679–684.
Get PDF (310K)